ANDA 30-Month Stay Of Approval Does Not Apply If Patent Case Is Settled
Executive Summary
FDA is proposing to void the 30-month Waxman/ Hatch stay of ANDA approval in cases where patent litigation between the applicant and the innovator company is dismissed or settled.
You may also be interested in...
Paxil Generics On Hold After Court Rejects FDA “Shared Exclusivity” Policy
No more generic versions of GlaxoSmithKline's Paxil will be approved before early March under a court decision rejecting FDA's approach to "shared exclusivity.
Paxil Generics On Hold After Court Rejects FDA “Shared Exclusivity” Policy
No more generic versions of GlaxoSmithKline's Paxil will be approved before early March under a court decision rejecting FDA's approach to "shared exclusivity.
ANDA Same-Day Filers Should Share Exclusivity, Industry Lawyer Says
FDA should allow ANDA applicants who file the first Paragraph IV certifications against a patent on the same day to share 180-day exclusivity, industry attorney David Adams said at a Food & Drug Law Institute conference in Washington, D.C. April 2